Top

Published in:

01-12-2018 | ASO Author Reflections

ASO Author Reflections: Predicting the Response of Esophageal Adenocarcinoma to Chemoradiotherapy Before Surgery Using MicroRNA Biomarkers Offers Hope to Improve Outcomes by Tailoring Treatment to Predicted Responses

Authors: George C. Mayne, BSc(Hons), PhD, David I. Watson, MBBS, MD, PhD, FRACS, FRCSEd(Hon), FAHMS, Karen Chiam, PhD, Damian J. Hussey, BSc(Hons), PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2018

Excerpt

Treatment for locally advanced esophageal adenocarcinoma usually involves neoadjuvant chemotherapy or chemoradiotherapy, followed by surgical resection. Neoadjuvant treatment improves survival rates, but only 30% of patients have complete pathological response, and survival is improved in only 10–15% of patients compared with surgery alone.1 Furthermore, neoadjuvant chemoradiotherapy can increase morbidity and make some patients unfit for surgery. Whilst some patients do benefit from neoadjuvant therapies, many more might actually be subjected to treatment toxicity and have their surgery delayed for no survival advantage. …

Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.CrossRef

Blum Murphy M, Xiao L, Patel VR, et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival—The University of Texas MD Anderson Cancer Center experience. Cancer 2017;123(21):4106–13.CrossRefPubMed

Peng R. The reproducibility crisis in science: a statistical counterattack. Significance. 2015;12(3):30–2.CrossRef

Chiam K, Mayne GC, Watson DI, et al. Identification of microRNA biomarkers of response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma using next generation sequencing. Ann Surg Oncol. 2018;25(9):2731–8.CrossRefPubMed

Title: ASO Author Reflections: Predicting the Response of Esophageal Adenocarcinoma to Chemoradiotherapy Before Surgery Using MicroRNA Biomarkers Offers Hope to Improve Outcomes by Tailoring Treatment to Predicted Responses
Authors: George C. Mayne, BSc(Hons), PhD
David I. Watson, MBBS, MD, PhD, FRACS, FRCSEd(Hon), FAHMS
Karen Chiam, PhD
Damian J. Hussey, BSc(Hons), PhD
Publication date: 01-12-2018
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue Special Issue 3/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-018-6958-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

ASO Author Reflections: Predicting the Response of Esophageal Adenocarcinoma to Chemoradiotherapy Before Surgery Using MicroRNA Biomarkers Offers Hope to Improve Outcomes by Tailoring Treatment to Predicted Responses

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 3/2018

ASO Author Reflections: Nodal Downstaging in Gastric Cancer

ASO Author Reflections: Non-GIST Sarcoma Liver Metastasis: How to Use the Past and Present to Predict the Future

ASO Author Reflections: Role of Preoperative Chemotherapy in the Treatment of Pancreatic Neuroendocrine Liver Metastases

Correction to: 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study

ASO Author Reflections: Endoscopic Ultrasonography for Determining Clinical T Classification for Esophageal Squamous Cell Carcinoma

ASO Author Reflections: Rationale for Organ Resection for Retroperitoneal Sarcomas